AEterna Zentaris Inc (NASDAQ:AEZS)
| 1.18 Data as of Jul 30 |  0.00 / 0.00%Today’s Change | 0.99 Today|||52-Week Range 1.75 | -14.49% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $66.7M |
Company Description
AEterna Zentaris, Inc. engages in the development of novel treatments in oncology and endocrinology, which currently investigating treatments for various unmet medical needs. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Quebec, Canada.
Contact Information
Æterna Zentaris, Inc. 1405, boulevard du Parc-Technologiqu Québec Quebec G1P 4P5 |
Employees
Shareholders
| Other institutional | 0.62% |
| Mutual fund holders | 0.01% |
| Individual stakeholders | -- |
Top Executives
| David A. Dodd | Chairman, President & Chief Executive Officer |
| Dennis Turpin | Chief Financial Officer & Senior Vice President |
| Richard Sachse | Senior VP, Chief Scientific & Medical Officer |
| Paul Burroughs | Communications Director & Head-Media Relations |
| Chantal Gravel | Director-Business Operations |
.
